| Name | Title | Contact Details |
|---|
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
HealthReveal is a clinical AI company dedicated to improving outcomes and quality of life for patients with chronic disease by enabling clinicians to deliver the most effective evidence-based treatments tailored to each patient’s unique circumstances, every time. By using machine learning and bridging each patient’s information with the latest medical guidelines, we predict individual patient health risks and disease progression and prescribe individual treatment interventions to mitigate risks, improve quality and reduce costs.
CliniComp is a global provider of Electronic Health Record (EHR) software and solutions that has enjoyed an unrivaled track record of performance and reliability in the most complex high acuity hospital environments for decades. Starting in 2014 CliniComp EHR extends the scope of coverage to Outpatient and Ancillaries such as Pharmacy, Radiology, and clinical laboratory information systems. This fully-integrated one stop expanded offering guarantees seamless CPOE and order/results management as well as transparent patient record viewing across all patient environments, distinct sites and time. Every Patient. Everywhere. For Life. The CCI system is certified for Stage 2 Meaningful Use and is currently supported internationally.
Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional techniques.
BMC Communications Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.